搜索
BCPE Perseus Investor Ord Shs (Proposed)
KLRA添加自选
23.170USD
+0.230+1.00%
收盘 06/01, 16:00（美东）报价延迟15分钟
2.97B总市值
--市盈率 TTM
关于 BCPE Perseus Investor Ord Shs (Proposed) 公司
Kailera Therapeutics Inc is a United States-based company. The Company is a clinical-stage biopharmaceutical company developing a broad and advanced therapeutic pipeline that is poised to deliver differentiated treatment options for obesity and related conditions. Its pipeline consists of clinical- and preclinical-stage programs with injectable peptides, oral peptides, and an oral small molecule.
BCPE Perseus Investor Ord Shs (Proposed)简介
公司代码KLRA
公司名称Kailera Therapeutics Inc
上市日期Apr 17, 2026
CEORenaud (Ron)
员工数量- -
证券类型Ordinary Share
年结日- -
公司地址180 Third Ave
城市WALTHAM
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02451
电话15084409475
网址https://www.kailera.com
公司代码KLRA
上市日期Apr 17, 2026
CEORenaud (Ron)
BCPE Perseus Investor Ord Shs (Proposed)公司高管
名称
名称/职务
职务
持股
持股变动
,
,
--
--
Mr. Ron Renaud
Mr. Ron Renaud
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul Burgess
Mr. Paul Burgess
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
--
--
Ms. Paula Cloghessy
Ms. Paula Cloghessy
Chief People Officer
Chief People Officer
--
--
Mr. Scott M. Akamine, J.D.
Mr. Scott M. Akamine, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Ms. Jamie Coleman
Ms. Jamie Coleman
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Douglas W. Pagan
Mr. Douglas W. Pagan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Scott Wasserman, M.D.
Dr. Scott Wasserman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Franklin K. (Frank) Clyburn, Jr.
Mr. Franklin K. (Frank) Clyburn, Jr.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
,
,
--
--
Mr. Ron Renaud
Mr. Ron Renaud
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul Burgess
Mr. Paul Burgess
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
--
--
Ms. Paula Cloghessy
Ms. Paula Cloghessy
Chief People Officer
Chief People Officer
--
--
Mr. Scott M. Akamine, J.D.
Mr. Scott M. Akamine, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Ms. Jamie Coleman
Ms. Jamie Coleman
Chief Commercial Officer
Chief Commercial Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 4月29日 周三
更新时间: 4月29日 周三
持股股东
股东类型
持股股东
持股股东
占比
Bain Capital Private Equity, LP
20.27%
Bain Capital Life Sciences Investors, LLC
17.43%
其他
62.30%
持股股东
持股股东
占比
Bain Capital Private Equity, LP
20.27%
Bain Capital Life Sciences Investors, LLC
17.43%
其他
62.30%
股东类型
持股股东
占比
Private Equity
20.27%
Investment Advisor
17.43%
其他
62.30%
机构持股
由于公司未披露，未能获取相关数据
报告期
机构数
持股数
持股占比
持股变动
暂无数据
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
暂无数据
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
